Skip to content

Press Releases

Swedish

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma issues new shares to Ergomed plc

(Stockholm, 20 February, 2020) Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 21 January 2020, issue 301,724 new shares to Ergomed plc (“Ergomed”), the CRO carrying out Asarina Pharma’s phase IIb PMDD study.

Full PDF

Asarina Pharma’s extraordinary general meeting

Today, on 21 January 2020, Asarina Pharma AB (publ) held an extraordinary general meeting (“EGM”) in Stockholm, Sweden. The EGM elected the chairman of the board of directors Paul de Potocki as chairman of the meeting and advokat Nina Johnsson with Fredersen Advokatbyrå to take minutes at the meeting. The EGM resolved upon, inter alia,…

Full PDF

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASARINA PHARMA AB (PUBL)

The shareholders of Asarina Pharma AB (publ) are hereby summoned to attend the Extraordinary General Meeting (“EGM”) on 21 January 2020, at 10.00 at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CET and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice, which…

Full PDF

First patient dosed in landmark Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.

Full PDF

Asarina Pharma AB (publ) Interim Report Q3 2019 released

Asarina Pharma CEO Peter Nordkild: “During an intense third quarter we achieved some important milestones. We enrolled the last patient in our landmark PMDD study, received FDA approval for our IND in menstrual migraine and included the first patient in our menstrual migraine study. After the end of the quarter a new directed share issue…

Full PDF
Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders 2023-05-23 09:02 Regulatory
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2023-05-22 11:15 Regulatory
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America 2023-05-05 13:33
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) 2023-04-18 10:39 Regulatory
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome 2023-04-01 14:20 Regulatory
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
Last Patient Last Visit for landmark Tourette Syndrome study 2023-02-02 09:45 Regulatory
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Patient recruitment completed in landmark Tourette syndrome study 2022-10-14 09:50 Regulatory
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD 2022-10-06 08:30 Regulatory
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
Next